NCT00116597View on ClinicalTrials.gov

Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2008

Conditions
Melanoma
Interventions
GENETIC

Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes

BIOLOGICAL

Intranodal booster immunizations with synthetic melanoma associated epitopes

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT00116597 - Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma | Biotech Hunter | Biotech Hunter